Leading Polish Medical Institutions for Berubicin Phase 2
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
Trials to be funded by a US$6 million grant previously awarded to WPD Pharmaceuticals
VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) --
WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that
in collaboration with CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS"), a biopharmaceutical company,
it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.
https://www.globenewswire.com/news-release/2020/04/30/2025162/0/en/WPD-Pharmaceuticals-and-CNS-Pharmaceuticals-Identify-Leading-Polish-Medical-Institutions-for-Berubicin-Phase-2-Clinical-Trial.html